These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 22370601)
41. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Osman N; O'Leary N; Mulcahy E; Barrett N; Wallis F; Hickey K; Gupta R Ir Med J; 2008 Sep; 101(8):245-7. PubMed ID: 18990955 [TBL] [Abstract][Full Text] [Related]
42. Borderline ovarian tumours: retrospective analysis of twenty-one cases. Saygili U; Uslu T; Erten O; Doğan E Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063 [TBL] [Abstract][Full Text] [Related]
43. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer. Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL Acta Obstet Gynecol Scand; 2006; 85(4):493-8. PubMed ID: 16612714 [TBL] [Abstract][Full Text] [Related]
44. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694 [TBL] [Abstract][Full Text] [Related]
46. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer. Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265 [TBL] [Abstract][Full Text] [Related]
48. High grade, advanced, serous ovarian cancer with low serum CA125 levels. Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544 [TBL] [Abstract][Full Text] [Related]
49. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282 [TBL] [Abstract][Full Text] [Related]
50. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer. Gaspar MJ; Diez M; Rodriguez A; Ratia T; Martin Duce A; Galvan M; Granell J; Coca C Anticancer Res; 2003; 23(4):3427-32. PubMed ID: 12926084 [TBL] [Abstract][Full Text] [Related]
51. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388 [TBL] [Abstract][Full Text] [Related]
52. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D J BUON; 2007; 12(1):99-104. PubMed ID: 17436409 [TBL] [Abstract][Full Text] [Related]
53. [Assessment of prognostic factors in common ovarian tumors of varying malignancy]. Demeter A; Várkonyi T; Csapó Z; Szánthó A; Oláh J; Papp Z Magy Onkol; 2004; 48(3):259-65. PubMed ID: 15520877 [TBL] [Abstract][Full Text] [Related]
54. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083 [TBL] [Abstract][Full Text] [Related]
55. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Olawaiye AB; Rauh-Hain JA; Withiam-Leitch M; Rueda B; Goodman A; del Carmen MG Gynecol Oncol; 2008 Sep; 110(3):293-8. PubMed ID: 18644620 [TBL] [Abstract][Full Text] [Related]
56. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Chen CA; Cheng WF; Lee CN; Chen TM; Kung CC; Hsieh FJ; Hsieh CY Gynecol Oncol; 1999 Aug; 74(2):235-40. PubMed ID: 10419737 [TBL] [Abstract][Full Text] [Related]
57. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer. Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750 [TBL] [Abstract][Full Text] [Related]
58. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296 [TBL] [Abstract][Full Text] [Related]
59. Immunohistological analysis of stress-induced phosphoprotein 1 in ovarian cancer patients with low serum cancer antigen 125 levels. Chao A; Lee LY; Hsueh C; Lin CY; Tsai CL; Chao AS; Lin CT; Chou HH; Chang TC; Wang TH Taiwan J Obstet Gynecol; 2013 Jun; 52(2):185-91. PubMed ID: 23915849 [TBL] [Abstract][Full Text] [Related]
60. Factors predictive of elevated serum CA125 levels in patients with epithelial ovarian cancer. Bouanène H; Harrabi I; Ferchichi S; Ben Limem H; Miled A Bull Cancer; 2007 Jul; 94(7):E18-22. PubMed ID: 17723943 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]